secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0000950170-24-013803
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic discontinues PKU study after data review; to cease operations, cut ~90% workforce, evaluate strategic options
--------------------------------------------------------------------------------

- Synpheny-3 study of SYNB1934 for PKU discontinued; internal data review found it unlikely to meet primary endpoint; safety acceptable.
- Company will cease operations and explore strategic alternatives including acquisition, merger, reverse merger, sale of assets, or dissolution.
- Workforce reduced by ~90%; CEO Aoife Brennan to depart March 9, 2024; estimated $6M in severance costs.
- Cash, equivalents, and short-term investments at Dec 31, 2023: $47.7M (unaudited).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017024013803/0000950170-24-013803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017024013803/sybx-20240212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-013803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer